Compulsory licensing – where is India heading? IAM (blog) (registration) ... were initiated in 2007 by Natco against Pfizer's drug Sutent (Sunitinib) (see "India to hear patentees' view in compulsory license cases"), which was used to treat gastrointestinal stromal tumours and Roche's Tarceva, used in lung cancer treatment. |
